Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
Key Insights
關鍵見解
- Shanghai Yizhong Pharmaceutical's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- The top 7 shareholders own 51% of the company
- 28% of Shanghai Yizhong Pharmaceutical is held by insiders
- 上海一中藥業擁有大量個人投資者的所有權,這表明關鍵決策受廣大公衆股東的影響
- 前7名股東擁有公司51%的股份
- 上海一中藥業28%的股份由內部人士持有
If you want to know who really controls Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are individual investors with 44% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
如果你想知道誰真正控制着上海一中藥業有限公司(SHSE: 688091),那麼你必須看看其股票登記處的構成。而持有最大份額的群體是擁有44%所有權的個人投資者。換句話說,該集團面臨最大的上行潛力(或下行風險)。
Following a 11% decrease in the stock price last week, individual investors suffered the most losses, but insiders who own 28% stock also took a hit.
繼上週股價下跌11%之後,個人投資者遭受的損失最大,但擁有28%股票的內部人士也受到了打擊。
Let's take a closer look to see what the different types of shareholders can tell us about Shanghai Yizhong Pharmaceutical.
讓我們仔細看看不同類型的股東能告訴我們關於上海一中藥業的什麼。
See our latest analysis for Shanghai Yizhong Pharmaceutical
查看我們對上海一中藥業的最新分析
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240129/0-58334eb8f490ff3290cbb17198009ba0-0-02edf3adc37049c33082a8f329fb3312.png/big)
What Does The Institutional Ownership Tell Us About Shanghai Yizhong Pharmaceutical?
關於上海一重藥業,機構所有權告訴我們什麼?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。
Since institutions own only a small portion of Shanghai Yizhong Pharmaceutical, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. It is not uncommon to see a big share price rise if multiple institutional investors are trying to buy into a stock at the same time. So check out the historic earnings trajectory, below, but keep in mind it's the future that counts most.
由於機構僅擁有上海一中藥業的一小部分股份,許多機構可能沒有花太多時間考慮這隻股票。但很明顯,有些人有;他們很喜歡它,足以買進。如果業務從此變得更加強大,我們可能會看到更多機構熱衷於收購的情況。如果多個機構投資者試圖同時買入股票,股價大幅上漲的情況並不少見。因此,請查看下面的歷史收益軌跡,但請記住,最重要的是未來。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240129/0-58334eb8f490ff3290cbb17198009ba0-1-453bfc1380617ea5a73cbed0ebbdc04e.png/big)
Hedge funds don't have many shares in Shanghai Yizhong Pharmaceutical. Looking at our data, we can see that the largest shareholder is the CEO Jingsong Zhou with 20% of shares outstanding. Shanghai Kaibao Pharmaceutical CO.,Ltd is the second largest shareholder owning 12% of common stock, and Duan Li holds about 7.4% of the company stock. Interestingly, the third-largest shareholder, Duan Li is also a Member of the Board of Directors, again, indicating strong insider ownership amongst the company's top shareholders.
對沖基金在上海一中藥業的股份不多。從我們的數據來看,我們可以看到最大股東是首席執行官周勁松,其已發行股份的20%。上海凱寶藥業有限公司, Ltd是第二大股東,擁有12%的普通股,段麗持有公司約7.4%的股份。有趣的是,第三大股東段麗也是董事會成員,這再次表明公司最大股東擁有強大的內部所有權。
On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.
經過進一步檢查,我們發現公司一半以上的股份由前7名股東持有,這表明較大股東的利益在一定程度上被較小的股東所平衡。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。據我們所知,沒有分析師對該公司進行報道,因此它可能處於雷達之下。
Insider Ownership Of Shanghai Yizhong Pharmaceutical
上海一中藥業的內部所有權
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。
It seems insiders own a significant proportion of Shanghai Yizhong Pharmaceutical Co., Ltd.. It is very interesting to see that insiders have a meaningful CN¥2.3b stake in this CN¥8.1b business. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
看來內部人士擁有上海一中藥業有限公司的很大一部分股份。有趣的是,內部人士在這項81億元的業務中擁有23億元人民幣的大量股份。大多數人會很高興看到董事會與他們一起投資。您不妨訪問這張顯示內部人士近期交易的免費圖表。
General Public Ownership
一般公有制
The general public-- including retail investors -- own 44% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
包括散戶投資者在內的公衆擁有該公司44%的股份,因此不容忽視。雖然這個團體不一定能做主,但它肯定會對公司的運營方式產生真正的影響。
Private Company Ownership
私人公司所有權
It seems that Private Companies own 13%, of the Shanghai Yizhong Pharmaceutical stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
私人公司似乎擁有上海一衆製藥13%的股份。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。
Public Company Ownership
上市公司所有權
Public companies currently own 12% of Shanghai Yizhong Pharmaceutical stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.
上市公司目前擁有上海一中藥業12%的股份。很難肯定地說,但這表明它們將商業利益交織在一起。這可能是一個戰略利害關係,因此值得關注這個領域的所有權變動。
Next Steps:
後續步驟:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should learn about the 3 warning signs we've spotted with Shanghai Yizhong Pharmaceutical (including 1 which is significant) .
儘管值得考慮擁有公司的不同群體,但還有其他因素更爲重要。爲此,你應該了解我們在上海一中藥業發現的3個警告信號(包括一個重要的警告信號)。
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
如果你更願意去另一家公司看看,一家財務狀況可能更好,那麼千萬不要錯過這份由強勁財務數據支持的有趣公司的免費名單。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。